Acquiring Company
Disruptive Pharma Holding AB (publ)
Acquired Company
Disruptive Pharma Holding AB (publ)
SwedenSwedenBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CarePharmaceuticalDescription
Disruptive Pharma AB has completed a reverse takeover of Disruptive Pharma Holding AB. The transaction was finalized on 27 July 2026, allowing Disruptive Pharma to commence trading on Nasdaq First North Growth Market under the new ticker symbol DPHA. This marks a significant milestone for the company as it transitions to a publicly listed entity.
Don't miss Disruptive Pharma Holding AB (publ)'s next move
Get an email the moment Disruptive Pharma Holding AB (publ) makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Disruptive Pharma Holding AB (publ)?
Disruptive Pharma Holding AB (publ) was acquired by Disruptive Pharma Holding AB (publ), based in Sweden. The deal was reported on August 18, 2026. Disruptive Pharma AB (publ) is a Swedish drug delivery technology company developing and commercializing Formulite®, a patented platform technology based on mesoporous magnesium carbonate (MMC). Disruptive Pharma Holding AB (publ) is privately held and operates in Biotechnology.
When did Disruptive Pharma Holding AB (publ) acquire Disruptive Pharma Holding AB (publ)?
Disruptive Pharma Holding AB (publ)'s acquisition of Disruptive Pharma Holding AB (publ) was reported on August 18, 2026. Disruptive Pharma AB has completed a reverse takeover of Disruptive Pharma Holding AB. The transaction was finalized on 27 July 2026, allowing Disruptive Pharma to commence trading on Nasdaq First North Growth Market under the new ticker symbol DPHA. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Disruptive Pharma Holding AB (publ) do?
Disruptive Pharma AB (publ) is a Swedish drug delivery technology company developing and commercializing Formulite®, a patented platform technology based on mesoporous magnesium carbonate (MMC). It is privately held, operating in Biotechnology, and is based in Sweden.